Recombinant monoclonal antibody to HSP60. This antibody intended for the prophylaxis and treatment of Rheumatoid arthritis (RA).
Figure 1 Dose response of prozumab binding to recombinant mammalian HSP60 in ELISA.
Ulmansky, R., Landstein, D., Moallem, E., Loeb, V., Levin, A., Meyuhas, R.,... & Naparstek, Y. (2015). A humanized monoclonal antibody against heat shock protein 60 suppresses murine arthritis and colitis and skews the cytokine balance toward an anti-inflammatory response. The Journal of Immunology, 194(11), 5103-5109.
Figure 2 Prozumab suppresses AA and CIA.
(A) AA was induced in Lewis rats. Rats were treated i.p. with prozumab (2.5 mg/kg) or PBS on day 15. MPS (5 mg/kg) was administered s.c. on day 15. Disease severity was evaluated every few days. Arthritis score is the mean ± SE of seven animals. *p < 0.05 for prozumab compared with PBS-treated rats. (B) Representative joint images of formalin-fixed paraffin-embedded sections prepared from rats treated with PBS or prozumab, as described in (A). Arrows indicate inflammation and fibrosis. Scale bars, 1 mm. (C) CIA was induced in DBA/1 mice. Mice were treated with PBS, prozumab (20 mg/kg), rituximab (20 mg/kg), or Enbrel (10 mg/kg). Two injections were given i.p.: on the day of arthritis onset and 4 d later. Paw diameter change was calculated based on the difference between paw diameter on the specified day and the initial paw diameter on the day of arthritis onset, as assessed by caliper. *p < 0.05 for prozumab compared with rituximab. (D) IL-10 levels (mean ± SE) in the sera of eight to nine CIA-induced mice, treated as described in (C) and sacrificed at the end of the study. *p < 0.05 for prozumab compared with all other treatment groups.
Ulmansky, R., Landstein, D., Moallem, E., Loeb, V., Levin, A., Meyuhas, R.,... & Naparstek, Y. (2015). A humanized monoclonal antibody against heat shock protein 60 suppresses murine arthritis and colitis and skews the cytokine balance toward an anti-inflammatory response. The Journal of Immunology, 194(11), 5103-5109.
Figure 3 Prozumab ameliorates colitis in IBD mouse models.
(A) Colitis was induced by TNBS. Reduction of body weight was measured in TNBS-induced colitis mice treated with prozumab (0.8 or 8 mg/kg), PBS, or rituximab (8 mg/kg). Treatment was administered i.p. twice, 2 d prior to and 1 d following intrarectal induction with TNBS. Body weight loss was calculated comparing mice weight at sacrifice to their weight at the intrarectal TNBS administration. Results are mean ± SE of eight mice per group. *p < 0.05 for prozumab (8 mg/kg) compared with PBS and rituximab-treated mice. (B) Representative images of formalin-fixed paraffin-embedded colon sections of mice treated with PBS and prozumab (8 mg/kg), as described in (A). Scale bars, 200 μm. (C) Histopathological analysis of the colon tissues taken from the TNBS-induced mice. Colon sections were scored for histopathologic changes. Results are the mean ± SE of seven to eight mice per group. *p < 0.05 for prozumab (8 mg/kg) compared with PBS and rituximab. (D) Disease score of prozumab (8 mg/kg) and control-treated mice in spontaneous colitis, developed in IL-10–deficient mice. Results are mean ± SE of six to seven mice per group. *p < 0.05 for prozumab compared with PBS and rituximab. (E) Mice survival in the various treatment groups of the spontaneous colitis model. *p < 0.05 for prozumab compared with PBS.
Ulmansky, R., Landstein, D., Moallem, E., Loeb, V., Levin, A., Meyuhas, R.,... & Naparstek, Y. (2015). A humanized monoclonal antibody against heat shock protein 60 suppresses murine arthritis and colitis and skews the cytokine balance toward an anti-inflammatory response. The Journal of Immunology, 194(11), 5103-5109.
Figure 4 Prozumab modulates cytokine secretion from human PBMCs.
IFN-γ (A) and IL-6 (B) levels in supernatants from anti–CD3-activated human PBMCs, incubated without (no Ab) or with 200 μg/ml prozumab or an isotype control Ab for 24 h, were determined by ELISA. Results obtained from each of the six naive donors tested are shown. The inset depicts the calculated mean ± SE of relative reduction in cytokine secretion from Ab-treated cells compared with nontreated cells (no Ab) for these six donors. For the calculation, cytokine secretion of nontreated cells (no Ab) for each donor was defined as 1. (C and D) Effect of prozumab dose on cytokine secretion (IFN-γ and IL-6, respectively) from anti–CD3-activated cryopreserved human PBMCs from two naive donors.
Ulmansky, R., Landstein, D., Moallem, E., Loeb, V., Levin, A., Meyuhas, R.,... & Naparstek, Y. (2015). A humanized monoclonal antibody against heat shock protein 60 suppresses murine arthritis and colitis and skews the cytokine balance toward an anti-inflammatory response. The Journal of Immunology, 194(11), 5103-5109.
Figure 5 Prozumab binding to Jurkat cells by FACS analysis.
(A) Jurkat cells (0.7–1 × 10⁶/ml) stained using prozumab and the isotype control mAbs, rituximab or Avastin, at a concentration of 100 μg/ml followed by allophycocyanin-conjugated anti-human Ab or the secondary Ab only. (B) Percentage binding of prozumab (80 μg/ml) or prozumab in the presence of 120 μg/ml soluble human HSP60 to Jurkat cells. Rituximab served as the isotype control. Detection was done using allophycocyanin-conjugated anti-human Ab.
Ulmansky, R., Landstein, D., Moallem, E., Loeb, V., Levin, A., Meyuhas, R.,... & Naparstek, Y. (2015). A humanized monoclonal antibody against heat shock protein 60 suppresses murine arthritis and colitis and skews the cytokine balance toward an anti-inflammatory response. The Journal of Immunology, 194(11), 5103-5109.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
DrMAB-1035 | Mouse Anti-HSPD1 Recombinant Antibody (clone YC181); Fab Fragment | ELISA | Mouse Fab |
FAMAB-0119JF-F(E) | Mouse Anti-HSPD1 Recombinant Antibody (clone II-13); Fab Fragment | WB, ELISA, FuncS | Mouse Fab |
FAMAB-0120JF-F(E) | Mouse Anti-HSPD1 Recombinant Antibody (clone ML-30); Fab Fragment | WB, ELISA, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-110CT | Anti-Human HSP60 Recombinant Antibody (prozumab) | Inhibit, ELISA | Humanized antibody |
TAB-110CT-F(E) | Anti-Human HSP60 Recombinant Antibody Fab Fragment (prozumab) | Inhibit, ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-018CT | Recombinant Mouse Anti-HSP60 Antibody | WB, IHC, FC |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-920CQ | Mouse Anti-HSPD1 Recombinant Antibody (clone 4B9/89) | Block, ELISA, ICC, IF, IHC, IHC-P, IP, WB | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1704 | Rabbit Anti-HSPD1 Recombinant Antibody (clone DS1704AB) | IHC-P, WB | Rabbit IgG |
MOR-0077-FY | Rabbit Anti-HSPD1 Recombinant Antibody (clone AFY0048) | ICC, IHC-P, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-LC2077 | PE-A*02:01/Human HSPD1 (KLSDGVAVL) MHC Tetramer | FCM |
CAT | Product Name | Application | Type |
---|---|---|---|
EPAF-1428LC | Mouse Anti-HSPD1 Recombinant Antibody (clone 9C9) | ELISA | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-0775-CN | Mouse Anti-HSPD1 Recombinant Antibody (clone 9-49) | WB, IF, IHC, FC | Mouse IgG2a |
MRO-0776-CN | Rabbit Anti-HSPD1 Recombinant Antibody (clone CBACN-289) | WB, IHC | Rabbit IgG |
MRO-0777-CN | Mouse Anti-HSPD1 Recombinant Antibody (clone 1-80) | WB, IF, IHC | Mouse IgG1 |
MRO-1944-CN | Rabbit Anti-HSPD1 Polyclonal Antibody (MRO-1944-CN) | WB, IF, IHC, FC | Rabbit IgG |
MRO-1945-CN | Rabbit Anti-HSPD1 Polyclonal Antibody (MRO-1945-CN) | WB, IF, IHC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-YF309 | Qa-1b/Human Hsp60 (GMKFDRGYI) MHC Monomer | MHC Multimer |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0119JF-S(P) | Mouse Anti-HSPD1 Recombinant Antibody (clone II-13); scFv Fragment | WB, ELISA, FuncS | Mouse scFv |
FAMAB-0120JF-S(P) | Mouse Anti-HSPD1 Recombinant Antibody (clone ML-30); scFv Fragment | WB, ELISA, FuncS | Mouse scFv |
There are currently no Customer reviews or questions for TAB-110CT-S(P). Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.